ஜார்ஜ் கெஂபல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஜார்ஜ் கெஂபல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஜார்ஜ் கெஂபல் Today - Breaking & Trending Today
Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors News provided by Share this article Share this article SAN MATEO, Calif., May 3, 2021 /PRNewswire/ Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of Elizabeth Grammer, Esq., to its board of directors. Ms. Grammer brings to her role as director over 25 years of experience advising privately held and publicly traded life sciences companies at all stages of development. George Kemble, Ph.D., Sagimet s chief executive officer, said, Elizabeth is a strategic and innovative thinker with a passion for developing, articulating and leading the execution of corporate strategy and will be a great addition to our board. We look forward to leveraging her extensive experience to help Sagimet grow our business. ....
Share this article Share this article SAN MATEO, Calif., March 16, 2021 /PRNewswire/ Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH. TVB-2640, is a wholly-owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs, and is the only enzyme in the human body capable of converting metabolized sugars into palmitate. In patients with NASH, increased FASN-mediated palmitate synthesis in the liver is the source of three key drivers of the disease: excess accumulation of liver fat, inflammation and fibrosis. ....
Sagimet Biosciences Names Dr. Eduardo Bruno Martins as Chief Medical Officer yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Ascletis Joins Sagimet s US$80 Million in Crossover Financing with Premium Investors News provided by Share this article Share this article HANGZHOU, China and SHAOXING, China, Feb. 11, 2021 /PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) announces today that Ascletis, through its wholly-owned subsidiary, participates in Sagimet Biosciences Inc. s US$80 million in crossover financing, led by an undisclosed public equity healthcare investment fund with participation from other existing investors (Kleiner Perkins, New Enterprise Associates (NEA) and Rock Springs), along with new investors (Altium, HM Capital, Invus and PFM) (Details referring to Sagimet Biosciences press release: https://www.sagimet.com/press-releases/). Prior to this crossover financing, Ascletis led a US$25 million Series E financing of Sagimet Biosciences in 2019. In conjunction with leading the Series E financing, Ascletis obtained an exclusive license from Sagimet Biosciences to develop, ....